



Theory article

Dynamics analysis of a diffusional immunosuppressive infection model with Beddington-DeAngelis functional response

Yuan Xue, Jinli Xu and Yuting Ding*

College of Science, Northeast Forestry University, Harbin 150040, China

* **Correspondence:** E-mail: yuting840810@163.com.

Abstract: This paper introduces diffusion into an immunosuppressive infection model with virus stimulation delay and Beddington-DeAngelis functional response. First, we study the stability of positive constant steady state solution and show that the Hopf bifurcation will exist under certain conditions. Second, we derive the normal form of the Hopf bifurcation for the model reduced on the center manifold by using the multiple time scales (MTS) method. Moreover, the direction and stability of the bifurcating periodic solution are investigated. Finally, we present numerical simulations to verify the results of theoretical analysis and provide corresponding biological explanations.

Keywords: immunosuppressive infection model; Beddington-DeAngelis functional response; delay; Hopf bifurcation; multiple time scales

1. Introduction

Some human pathogens, such as hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV), possess the ability to suppress the immune response and damage the immune system, ultimately leading to the development of certain chronic diseases and even tumors [1]. In recent years, researchers have extensively studied numerous models pertaining to these infections [2–4]. In recent years, there has been notable progress in treating these infections. For example, the latest direct-acting antiviral drugs (DAA) for HCV can cure the majority of cases quickly, with cure rates reaching up to 95% [5, 6]. For HBV, the optimal approach involves long-term medication to manage the condition, reduce viral transmission and stabilize host immune system [7, 8]. Similarly, antiretroviral therapy (ART) is commonly used to suppress HIV replication [9]. Notably, a small group of elite controllers can naturally manage HIV without treatment [10]. However, challenges persist, including drug resistance and the risk of viral replication or recurrence [5–9]. In the past few years, immune checkpoint therapy, a method that shows significant efficacy in completely eliminating tumor cells for certain types of tumors, has been discovered, which activates the host's own immune system to inhibit

tumor growth and spread [11–13]. Enhancing antiviral treatment by strengthening specific immune responses has become a hot topic among researchers.

In 2003, Komarova et al. [1] first established an immunosuppressive infection model to investigate the relationship between drug efficacy and treatment duration, the model is given as follows:

$$\begin{cases} \frac{dy}{dt} = ry\left(1 - \frac{y}{K}\right) - ay - pyz, \\ \frac{dz}{dt} = \frac{cyz}{1+\eta y} - bz - qyz := zf(y), \end{cases} \quad (1.1)$$

where y , z denote the population size of viruses and immune cells at time t , respectively. Viral reproduction follows logistic growth, r represents the viral replication rate at a viral load K . It is hypothesized that the virus population undergoes decay at a rate a , and immune cells eliminate the viruses at a rate pyz . Furthermore, immune cells are suppressed by the viruses at a rate qyz and die at a rate b . In the context of antigenic stimulation, the proliferation of immune cells relies on both the viruses and immune cells, and it can be quantified by the expansion function

$$\Phi(y, z) = \frac{cyz}{1 + \eta y},$$

where η represents the inhibitory effects of the viruses on the proliferation of immune cells.

In 2014, Shu et al. [14] introduced a time delay in the immune expansion function of the model described in [1] and studied the existence of Hopf bifurcation and periodic solutions. In 2017, Tian et al. [15] incorporated diffusion into the model presented in [14] and studied the direction and stability of Hopf bifurcations. However, viruses require a certain amount of time to effectively stimulate immune cells. We refer to this time period as the virus stimulation delay, denoted as τ . The immune cells at time t are essentially activated by the viruses at time $t - \tau$. Therefore, in 2021, Li et al. [16] studied the function as follows:

$$\Phi(y_\tau, z) = \frac{cy(t - \tau)z}{1 + \eta y(t - \tau)}.$$

However, it has been noted by Wodarz (see pp 31, Chapter 2 in [17]) that the growth rate of immune cells, denoted as $zf(y)$, in all of these models was assumed to be directly proportional to z , but nonlinearity can better capture the realistic dynamics. Thus, a more realistic model, proposed by De Boer and Perelson [18, 19] in 1995–1997, has been suggested to provide a better representation of the actual dynamics. In this model, the immune expansion function is described by the well-known Beddington-DeAngelis functional response [20, 21], the form of which is as follows:

$$\Phi(y, z) = \frac{cyz}{1 + \eta y + sz}.$$

It was initially used in predator-prey models [22–24]. The parameter s in the function represents the strength of competition between immune responses. This immune expansion function provides a more biologically realistic description of the interactions and competitive relationships between virus populations and immune cell populations within a host [25]. Thus the Beddington-DeAngelis functional response has also been widely discussed in immunosuppressive infection models [26–28].

In 2023, Chen et al. [29] introduced the Beddington-DeAngelis functional response into the immunosuppressive infection model established by Komarova et al. [1], the model is as follows:

$$\begin{cases} \frac{dy}{dt} = ry\left(1 - \frac{y}{K}\right) - ay - pyz, \\ \frac{dz}{dt} = \frac{cy(t-\tau)z}{1+\eta y(t-\tau)+sz} - bz - qyz. \end{cases} \quad (1.2)$$

In [29], Chen et al. discussed the local and global stability of equilibrium points in the absence of delay, as well as the stability and Hopf bifurcation of model (1.2) when delay is present. They designed antiviral drug treatment strategies from the perspectives of adaptivity and feasibility of immune competition strength and viral suppression intensity.

In practical problems, the spread of viruses within a host is possible. Thus we introduce the diffusion into the model proposed by Chen et al. in [29]. As far as we know, this task has not been attempted yet. Therefore, we study the reaction-diffusion system under the Neumann boundary condition as follows:

$$\begin{cases} \frac{\partial y(x, t)}{\partial t} = d_1 \Delta y(x, t) + ry(x, t) \left(1 - \frac{y(x, t)}{K} \right) - ay(x, t) - py(x, t)z(x, t), \\ \frac{\partial z(x, t)}{\partial t} = d_2 \Delta z(x, t) + \frac{cy(x, t - \tau)z(x, t)}{1 + \eta y(x, t - \tau) + sz(x, t)} - bz(x, t) - qy(x, t)z(x, t), \\ \partial_\nu y(x, t) = \partial_\nu z(x, t) = 0, \quad x \in \partial\Omega, t > 0, \\ y(x, t) = \psi_1(x, t), z(x, t) = \psi_2(x, t), \quad x \in \Omega, t \in [-\tau, 0], \end{cases} \quad (1.3)$$

where $\Omega = (0, l\pi)$ with $l > 0$, $y = y(x, t)$ and $z = z(x, t)$ denoting the population densities of viruses and immune cells at location x and time t , respectively. The parameters s and τ stand for the competition intensity between immune responses and the viral stimulation delay, respectively. The diffusion rates of viruses and immune cells are d_1 and d_2 , respectively. The same parameters as in model (1.1) have the same biological meanings. Note that all parameters in (1.3) remain nonnegative.

The remaining sections of the paper are organized as follows: Section 2 discusses the local asymptotic stability of the positive constant steady state solution and the existence of Hopf bifurcation. In Section 3, we derive the normal form of the Hopf bifurcation by using the multiple time scales (MTS) method. Section 4 presents numerical simulations to illustrate the theoretical analysis, and the conclusion is given in Section 5.

2. Stability of the positive constant steady state solution and existence of Hopf bifurcation

In this section, we concentrate on studying the local asymptotic stability of the positive constant steady state solution and the existence of Hopf bifurcation for system (1.3). From a biological perspective, we only focus on the positive constant steady state solution (y_*, z_*) . It is evident that (y_*, z_*) satisfies the following equations:

$$\begin{aligned} ry_* \left(1 - \frac{y_*}{K} \right) - ay_* - py_*z_* &= 0, \\ \frac{cy_*z_*}{1 + \eta y_* + sz_*} - bz_* - qy_*z_* &= 0. \end{aligned} \quad (2.1)$$

Then we can write y_* in terms of z_* as

$$y_* = K \left(1 - \frac{a + pz_*}{r} \right), \quad (2.2)$$

substituting Eq (2.2) into Eq (2.1), we obtain

$$Az^2 + Bz + C = 0,$$

where

$$\begin{aligned} A &= -q\eta K^2 p^2 + Kpqrs, \\ B &= 2q\eta(r-a)pK^2 + [r(b\eta - c + q)p - (r-a)rqs]K - br^2s, \\ C &= -q\eta(r-a)^2K^2 + r(b\eta - c + q)(a-r)K - br^2. \end{aligned} \quad (2.3)$$

Denote

$$\Delta_1 \triangleq B^2 - 4AC. \quad (2.4)$$

Lemma 1. For the positive constant steady state solution of system (1.3), we have the following results.

- (i) If $\Delta_1 > 0$, $AC > 0$, $AB < 0$, and $a + pz_* < r$ holds, then system (1.3) has two positive constant steady state solutions, $E_{*1} = (y_{*1}, z_{*1})$ and $E_{*2} = (y_{*2}, z_{*2})$. Here $z_{*1} = \frac{-B + \sqrt{\Delta_1}}{2A}$, $z_{*2} = \frac{-B - \sqrt{\Delta_1}}{2A}$, with $y_{*1} = K\left(1 - \frac{a+pz_{*1}}{r}\right)$ and $y_{*2} = K\left(1 - \frac{a+pz_{*2}}{r}\right)$;
- (ii) If $\Delta_1 > 0$, $AC < 0$, and $a + pz_* < r$ holds, then system (1.3) has one positive constant steady state solution $E_{*3} = (y_{*3}, z_{*3})$. Here $z_{*3} = \frac{-B + \sqrt{\Delta_1}}{2A}$, with $y_{*3} = K\left(1 - \frac{a+pz_{*3}}{r}\right)$;
- (iii) If $\Delta_1 = 0$, $AB < 0$, and $a + pz_* < r$ holds, then system (1.3) has one positive constant steady state solution $E_{*4} = (y_{*4}, z_{*4})$. Here $z_{*4} = \frac{-B}{2A}$, with $y_{*4} = K\left(1 - \frac{a+pz_{*4}}{r}\right)$.

Without loss of generality, we denote E_{*1} , E_{*2} , E_{*3} , and E_{*4} as E_* . Therefore, when the parameters of system (1.3) satisfy any one of the conditions (i)–(iii) of Lemma 1, the positive constant steady state solution $E_* = (y_*, z_*)$ exists.

Now, we analyze the stability of $E_* = (y_*, z_*)$. Set $U(x, t) = (y(x, t), z(x, t))^T$, then the linearization of system (1.3) at E_* can be written as

$$\frac{\partial U(x, t)}{\partial t} = D\Delta U(x, t) + A_*U(x, t) + B_*U(x, t - \tau), \quad (2.5)$$

where

$$\begin{aligned} D &= \begin{pmatrix} d_1 & 0 \\ 0 & d_2 \end{pmatrix}, \quad A_* = \begin{pmatrix} -\frac{ry_*}{K} & -py_* \\ -qz_* & -\frac{z_*s(b+qy_*)^2}{cy_*} \end{pmatrix}, \\ B_* &= \begin{pmatrix} 0 & 0 \\ \frac{z_*(b+qy_*)[c-\eta(b+qy_*)]}{cy_*} & 0 \end{pmatrix}. \end{aligned}$$

Therefore, the characteristic equation of the linearization of system (1.3) at E_* can be obtained as

$$\lambda^2 + T_n\lambda + N_n + C_0(e^{-\lambda\tau}b_0 - q) = 0, \quad n \in \mathbb{N}_0 = \{0, 1, 2, 3, \dots\}, \quad (2.6)$$

with

$$\begin{aligned} T_n &= \frac{n^2}{l^2}d_1 + \frac{n^2}{l^2}d_2 + \frac{ry_*}{K} + \frac{z_*s(b+qy_*)^2}{cy_*}, \\ N_n &= \frac{n^4}{l^4}d_1d_2 + \frac{n^2}{l^2}d_1 \cdot \frac{z_*s(b+qy_*)^2}{cy_*} + \frac{n^2}{l^2}d_2 \cdot \frac{ry_*}{K} + \frac{rz_*s(b+qy_*)^2}{Kc}, \\ C_0 &= py_*z_*, \\ b_0 &= \frac{(b+qy_*)[c-\eta(b+qy_*)]}{cy_*}. \end{aligned}$$

Lemma 2. When $\tau = 0$, the positive constant steady state solution E_* of system (1.3) is locally asymptotically stable if $b_0 - q > 0$.

Proof. When $\tau = 0$, characteristic Eq (2.6) becomes

$$\lambda^2 + T_n \lambda + N_n + C_0(b_0 - q) = 0, \quad n \in \mathbb{N}_0. \quad (2.7)$$

It is clear that $T_n > 0$, $N_n > 0$, thus if $b_0 - q > 0$ holds, the real parts of the roots of Eq (2.6) are negative. Thus, E_* is locally asymptotically stable.

This completes the proof. \square

Suppose that $\lambda = i\omega$ ($\omega > 0$) is a root of Eq (2.6), then we have

$$\begin{cases} C_0 b_0 \cos(\omega\tau) = \omega^2 + C_0 q - N_n, \\ C_0 b_0 \sin(\omega\tau) = T_n \omega. \end{cases} \quad (2.8)$$

Square and add above equations, then denote $g \triangleq \omega^2$. We obtain

$$\varphi(g) \triangleq g^2 + (2C_0 q - 2N_n + T_n^2)g + (C_0 q - N_n)^2 - C_0^2 b_0^2 = 0. \quad (2.9)$$

Next, we will discuss the existence of ω . For the sake of convenience in our discussion, we present the following assumed conditions:

- (H1) $\Delta_2 = 0$, $2C_0 q - 2N_n + T_n^2 < 0$,
- (H2) $\Delta_2 > 0$, $(C_0 q - N_n)^2 - C_0^2 b_0^2 < 0$,
- (H3) $\Delta_2 > 0$, $2C_0 q - 2N_n + T_n^2 < 0$, $(C_0 q - N_n)^2 - C_0^2 b_0^2 > 0$,
- (H4) $\Delta_2 < 0$,
- (H5) $\Delta_2 > 0$, $2C_0 q - 2N_n + T_n^2 > 0$, $(C_0 q - N_n)^2 - C_0^2 b_0^2 > 0$,

where $\Delta_2 = (2C_0 q - 2N_n + T_n^2)^2 - 4[(C_0 q - N_n)^2 - C_0^2 b_0^2]$, and N_n, T_n, b_0, C_0 are given in Eq (2.6).

Lemma 3. When $\tau > 0$, concerning the cases of positive roots of Eq (2.9), we have the following results:

- (i) Equation (2.9) has a unique positive root if (H1) or (H2) is satisfied, then the positive constant steady state solution of system (1.3) will not exhibit stability switches,
- (ii) Equation (2.9) has two positive roots if (H3) is satisfied, then the positive constant steady state solution of system (1.3) will exhibit stability switches,
- (iii) Equation (2.9) has no positive root if (H4) or (H5) is satisfied.

Proof. If the condition (H1) is satisfied, we have $g_1 = g_2$, $g_1 + g_2 = -(2C_0 q - 2N_n + T_n^2) > 0$. If the condition (H2) is satisfied, we have $g_1 \cdot g_2 = (C_0 q - N_n)^2 - C_0^2 b_0^2 < 0$. Both of them imply that there is a unique positive root g satisfying Eq (2.9). This proves (i).

Similarly, we conclude (ii)–(iii). \square

Considering the scenario with only a pair of purely imaginary roots, the unique positive ω that satisfies Eq (2.9) can be described as follows:

$$\omega_n^+ = \sqrt{\frac{-(2C_0q - 2N_n + T_n^2) + \sqrt{\Delta_2}}{2}}, \quad n \in \mathbb{N}_0. \quad (2.10)$$

Denote

$$R_n \triangleq \sin(\omega_n^+ \tau) = \frac{T_n \omega_n^+}{C_0 b_0}, \quad (2.11)$$

$$Q_n \triangleq \cos(\omega_n^+ \tau) = \frac{(\omega_n^+)^2 + C_0 q - N_n}{C_0 b_0}.$$

Now, define a set

$$I_1 = \{n \in \mathbb{N}_0 \mid \text{such that (H1) or (H2) holds}\}. \quad (2.12)$$

From Eq (2.11), we obtain

$$\tau_{n,j}^+ = \begin{cases} \frac{1}{\omega_n^+} (\arccos(Q_n) + 2j\pi), & \text{for } R_n \geq 0, \\ \frac{1}{\omega_n^+} (2\pi - \arccos(Q_n) + 2j\pi), & \text{for } R_n < 0. \end{cases} \quad n \in I_1, \quad j \in \mathbb{N}_0. \quad (2.13)$$

From Eq (2.13), we find that $\{\tau_{n,j}^+\}_{j=0}^\infty$ is increasing about j for some fixed $n \in I_1$. Thus, for fixed n , one has $\tau_{n,0}^+ = \min_{j \in \mathbb{N}_0} \{\tau_{n,j}^+\}$. To investigate the stability of E_* , we define the smallest critical value of time delay

$$\tau_c = \min \{\tau_{n,0}^+ \mid n \in I_1\}. \quad (2.14)$$

Theorem 1. *If $b_0 - q > 0$ and one of the two conditions (H1) or (H2) is satisfied, then the positive constant steady state solution E_* of system (1.3) is locally asymptotically stable when $\tau \in [0, \tau_c)$, and unstable when $\tau \in (\tau_c, \infty)$. Moreover, system (1.3) undergoes the Hopf bifurcation at E_* when $\tau = \tau_c$, where τ_c is given in Eq (2.14).*

Proof. Differentiating the both sides of the characteristic Eq (2.6) with respect to time delay τ gives rise to

$$\left(\frac{d\lambda}{d\tau}\right)^{-1} = \frac{2\lambda + T_n}{\lambda [C_0 q - (\lambda^2 + T_n \lambda + N_n)]} - \frac{\tau}{\lambda}.$$

As a result, one has

$$\left(\operatorname{Re} \frac{d\lambda}{d\tau}\right)^{-1} \Big|_{\tau=\tau_{n,j}^+} = \frac{\sqrt{\Delta_2}}{T_n^2 (\omega_{n,j}^+)^2 + [N_n - C_0 q - (\omega_{n,j}^+)^2]^2} > 0, \quad n \in I_1, \quad j \in \mathbb{N}_0. \quad (2.15)$$

This means that the transversality condition is satisfied.

This completes the proof. \square

3. Normal form of the Hopf bifurcation

We have obtained that under certain conditions, the characteristic Eq (2.6) of system (1.3) has a unique pair of purely imaginary roots $\lambda = \pm i\omega_n^+$, then system (1.3) undergoes the Hopf bifurcation at E_* when $\tau = \tau_c$, with τ_c as given at (2.14). In this section, we will utilize the method of MTS to derive the normal form of the Hopf bifurcation.

Denote that

$$f(y(x, t - \tau), z(x, t)) \triangleq \frac{cy(x, t - \tau)z(x, t)}{1 + \eta y(x, t - \tau) + sz(x, t)} \quad (3.1)$$

and

$$\begin{aligned} L &= 1 + \eta y_* + sz_*, \\ \alpha &= 1 + sz_*, \\ \beta &= 1 + \eta y_*. \end{aligned} \quad (3.2)$$

Perform a Taylor expansion of $f(y(x, t - \tau), z(x, t))$ at E_* , then we obtain

$$\begin{aligned} f(y(x, t - \tau), z(x, t)) &= \frac{cy_*z_*}{L} + \frac{cz_*\alpha}{L^2}(y(x, t - \tau) - y_*) + \frac{cy_*\beta}{L^2}(z(x, t) - z_*) - \frac{c\eta z_*\alpha}{L^3}(y(x, t - \tau) - y_*)^2 \\ &+ \frac{c(2\eta y_*z_*s + \eta y_* + \alpha)}{L^3}(y(x, t - \tau) - y_*)(z(x, t) - z_*) - \frac{csy_*\beta}{L^3}(z(x, t) - z_*)^2 \\ &+ \frac{c\eta^2 z_*\alpha}{L^4}(y(x, t - \tau) - y_*)^3 + c\eta \left[\frac{3sz_*\alpha}{L^4} - \frac{1 + 2sz_*}{L^3} \right] (y(x, t - \tau) - y_*)^2(z(x, t) - z_*) \\ &+ \frac{cs \left[-1 - z_*s(1 + 2\eta y_*) + \eta^2 y_*^2 \right]}{L^4} (y(x, t - \tau) - y_*)(z(x, t) - z_*)^2 \\ &+ \frac{cs^2 y_*\beta}{L^4} (z(x, t) - z_*)^3 + \dots \end{aligned} \quad (3.3)$$

Now, we set $\hat{y}(x, t) = y(x, \tau t) - y_*$, $\hat{z}(x, t) = z(x, \tau t) - z_*$, and still denote $\hat{y}(x, t)$ and $\hat{z}(x, t)$ by $y(x, t)$

and $z(x, t)$, respectively. Then system (1.3) takes the form

$$\left\{ \begin{aligned} \frac{\partial y(x, t)}{\partial t} &= \tau \left[d_1 \Delta y(x, t) + r(y(x, t) + y_*) \left(1 - \frac{y(x, t) + y_*}{K} \right) - a(y(x, t) + y_*) - p(y(x, t) + y_*)(z(x, t) + z_*) \right], \\ \frac{\partial z(x, t)}{\partial t} &= \tau \left[d_2 \Delta z(x, t) + \frac{cz_*\alpha}{L^2} y(x, t - 1) + \frac{cy_*\beta}{L^2} z(x, t) - \frac{c\eta z_*\alpha}{L^3} y^2(x, t - 1) \right. \\ &\quad + \frac{c(2\eta y_* z_* s + \eta y_* + \alpha)}{L^3} y(x, t - 1)z(x, t) - \frac{csy_*\beta}{L^3} z^2(x, t) + \frac{c\eta^2 z_*\alpha}{L^4} y^3(x, t - 1) \\ &\quad + c\eta \left[\frac{3sz_*\alpha}{L^4} - \frac{1 + 2sz_*}{L^3} \right] y^2(x, t - 1)z(x, t) + \frac{cs[-1 - z_*s(1 + 2\eta y_*) + \eta^2 y_*^2]}{L^4} y(x, t - 1)z^2(x, t) \\ &\quad \left. + \frac{cs^2 y_*\beta}{L^4} z^3(x, t) - bz(x, t) - q[y(x, t)z(x, t) + y(x, t)z_* + z(x, t)y_*] \right], \\ \partial_\nu y(x, t) &= \partial_\nu z(x, t) = 0, \quad x \in \partial\Omega, \quad t > 0, \\ y(x, t) &= \psi_1(x, t), \quad z(x, t) = \psi_2(x, t), \quad x \in \Omega = (0, l\pi), \quad t \in [-\tau, 0]. \end{aligned} \right. \quad (3.4)$$

Let $h = (h_{11}, h_{12})^T$ be the eigenvector of the characteristic matrix of the linearization of system Eq (3.4) at E_* corresponding to the eigenvalue $i\omega\tau$ and $h^* = d(h_{21}, h_{22})^T$ be the eigenvector of the adjoint matrix corresponding to the eigenvalue $-i\omega\tau$. They satisfy the inner product

$$\langle h^*, h \rangle = \bar{h}^{*T} \cdot h = 1.$$

By calculating, we have

$$\begin{aligned} h_{11} &= 1, \\ h_{12} &= -\frac{1}{py_*} \left(i\omega + \frac{n^2}{l^2} d_1 + \frac{r}{K} y_* \right), \\ h_{21} &= -\frac{1}{py_*} \left[-i\omega + \frac{n^2}{l^2} d_2 + \frac{z_*s(b + qy_*^2)}{cy_*} \right], \\ h_{22} &= 1, \\ d &= (h_{21}\bar{h}_{11} + h_{22}\bar{h}_{12})^{-1}. \end{aligned} \quad (3.5)$$

Consider the delay τ as a bifurcation parameter, let $\tau = \tau_c + \varepsilon\mu$, where τ_c is the critical point of the Hopf bifurcation, given as Eq (2.14). μ is a small perturbation parameter, and ε is the characteristic scale used for non-dimensionalization. The solution of Eq (3.4) is assumed to take the form:

$$U(x, t) = U(x, T_0, T_1, T_2, \dots) = \sum_{k=1}^{+\infty} \varepsilon^k U_k(x, T_0, T_1, T_2, \dots), \quad (3.6)$$

where

$$\begin{aligned} U(x, T_0, T_1, T_2, \dots) &= (y(x, T_0, T_1, T_2, \dots), z(x, T_0, T_1, T_2, \dots))^T, \\ U_k(x, T_0, T_1, T_2, \dots) &= (y_k(x, T_0, T_1, T_2, \dots), z_k(x, T_0, T_1, T_2, \dots))^T. \end{aligned} \quad (3.7)$$

The derivative with respect to t is now transformed into

$$\frac{\partial}{\partial t} = \frac{\partial}{\partial T_0} + \varepsilon \frac{\partial}{\partial T_1} + \varepsilon^2 \frac{\partial}{\partial T_2} + \dots = D_0 + \varepsilon D_1 + \varepsilon^2 D_2 + \dots, \quad (3.8)$$

with the differential operator $D_i = \frac{\partial}{\partial T_i}$, $i \in \mathbb{N}_0$.

Let

$$\begin{aligned} y_j &= y_j(x, T_0, T_1, T_2, \dots), \quad y_{j,1} = y_j(x, T_0 - 1, T_1, T_2, \dots), \\ z_j &= z_j(x, T_0, T_1, T_2, \dots), \quad z_{j,1} = z_j(x, T_0 - 1, T_1, T_2, \dots), \end{aligned} \quad (3.9)$$

where $j \in \mathbb{N} = \{1, 2, 3, \dots\}$. According to Eqs (3.7) and (3.8), we get

$$\frac{\partial U}{\partial t} = \varepsilon D_0 U_1 + \varepsilon^2 D_1 U_1 + \varepsilon^3 D_2 U_1 + \varepsilon^2 D_0 U_2 + \varepsilon^3 D_1 U_2 + \varepsilon^3 D_0 U_3 + \dots. \quad (3.10)$$

To deal with the delayed terms, we expand $y(x, t - 1)$ at $y(x, T_0 - 1, T_1, T_2, \dots)$, then we have

$$y(x, t - 1) = \varepsilon y_{11} + \varepsilon^2 y_{21} + \varepsilon^3 y_{31} - \varepsilon^2 D_1 y_{11} - \varepsilon^3 D_1 y_{21} - \varepsilon^3 D_2 y_{11} + \dots, \quad (3.11)$$

where $y_{j1} = y_j(x, T_0 - 1, T_1, T_2, \dots)$, $j \in \mathbb{N}$.

Substituting Eqs (3.6)–(3.11) into Eq (3.4) will lead to some perturbation equations. By collecting the coefficients with respect to different powers of ε , we can obtain a set of ordered linear differential equations. First, for the ε -order terms, we have

$$\begin{cases} D_0 y_1 - \tau_c \left[r y_1 - a y_1 + d_1 \Delta y_1 - \frac{2r y_* y_1}{K} - p y_1 z_* - p y_* z_1 \right] = 0, \\ D_0 z_1 - \tau_c \left[d_2 \Delta z_1 + \frac{c z_* \alpha y_{11}}{L^2} + \frac{c y_* \beta z_1}{L^2} - b z_1 - q(y_* z_1 + y_1 z_*) \right] = 0, \end{cases} \quad (3.12)$$

where L, α, β are given by Eq (3.2). Thus the solution of Eq (3.12) can be expressed in the form as follows:

$$\begin{aligned} y_1 &= G(T_1, T_2, \dots) e^{i\omega \tau_c T_0} h_{11} \cos(nx) + c.c., \\ z_1 &= G(T_1, T_2, \dots) e^{i\omega \tau_c T_0} h_{12} \cos(nx) + c.c., \end{aligned} \quad (3.13)$$

where h_{11}, h_{12} are given by Eq (3.5), and $c.c.$ represents the complex conjugate of the previous term. Next, for the ε^2 -order terms, we obtain

$$\begin{cases} D_0 y_2 - \tau_c \left[r y_2 - a y_2 + d_1 \Delta y_2 - \frac{2r y_* y_2}{K} - p y_2 z_* - p y_* z_2 \right] \\ = -D_1 y_1 - \frac{\tau_c r y_1^2}{K} - \mu a y_1 + \mu r y_1 + \mu d_1 \Delta y_1 - \mu p y_1 z_* - \mu p y_* z_1 - \frac{2\mu r y_* y_1}{K} - \tau_c p y_1 z_1, \\ D_0 z_2 - \tau_c \left[d_2 \Delta z_2 + \frac{c z_* \alpha y_{21}}{L^2} + \frac{c y_* \beta z_2}{L^2} - b z_2 - q(y_* z_2 + y_2 z_*) \right] \\ = \tau_c \left[\frac{-c z_* \alpha D_1 y_{11}}{L^2} - \frac{c \eta z_* \alpha y_{11}^2}{L^3} + \frac{c(2\eta y_* z_* s + \eta y_* + \alpha) y_{11} z_1}{L^3} - \frac{c y_* \beta z_1^2}{L^3} - q y_1 z_1 \right] \\ + \mu \left[d_2 \Delta z_1 + \frac{c z_* \alpha y_{11}}{L^2} + \frac{c y_* \beta z_1}{L^2} - b z_1 - q(y_* z_1 + y_1 z_*) \right] - D_1 z_1, \end{cases} \quad (3.14)$$

where L, α, β are given by Eq (3.2). We substitute solution Eq (3.13) into the right side of Eq (3.14), and denote the coefficient vector of $e^{i\omega\tau_c T_0}$ as m_1 , which satisfies the solvability condition

$$\langle h^*, (m_1, \cos(nx)) \rangle = 0.$$

Then one has

$$\frac{\partial G}{\partial T_1} = M\mu G, \quad (3.15)$$

where

$$M = \frac{\bar{h}_{21}M_1 + \bar{h}_{22}M_2}{h_{11}\bar{h}_{21} + h_{12}\bar{h}_{22} + \frac{\tau_c z_* \alpha}{L^2} e^{-i\omega\tau_c} h_{11}\bar{h}_{22}}, \quad (3.16)$$

with

$$M_1 = -ah_{11} + rh_{11} - n^2 d_1 h_{11} - pz_* h_{11} - py_* h_{12} - \frac{2ry_*}{K} h_{11},$$

$$M_2 = -n^2 d_2 h_{12} + \frac{cz_* \alpha}{L^2} e^{-i\omega\tau_c} h_{11} + \frac{cy_* \beta}{L^2} h_{12} - bh_{12} - qy_* h_{12} - qz_* h_{11}.$$

Suppose that the solution of Eq (3.14) is

$$\begin{cases} y_2 = \sum_{k=0}^{+\infty} (\eta_{0,k} G \bar{G} + \eta_{1,k} e^{2i\omega\tau_c T_0} G^2 + \bar{\eta}_{1,k} e^{-2i\omega\tau_c T_0} \bar{G}^2) \cos(kx), \\ z_2 = \sum_{k=0}^{+\infty} (\zeta_{0,k} G \bar{G} + \zeta_{1,k} e^{2i\omega\tau_c T_0} G^2 + \bar{\zeta}_{1,k} e^{-2i\omega\tau_c T_0} \bar{G}^2) \cos(kx). \end{cases} \quad (3.17)$$

Let $C_k = \langle \cos(nx) \cos(nx), \cos(kx) \rangle = \int_0^{l\pi} \cos(nx) \cos(nx) \cos(kx) dx$. Besides, we have

$$\int_0^{l\pi} \cos(nx) \cos(kx) dx = \begin{cases} 0 & k \neq n, \\ \frac{l\pi}{2} & k = n \neq 0, \\ l\pi & k = n = 0. \end{cases}$$

We substitute solution Eqs (3.13) and (3.17) into Eq (3.14), then make the inner product with $\cos(kx)$ on both sides of the obtained equation, where $k \in \mathbb{N}_0$. By adding the obtained results, we can compare the coefficients in front of terms G^2 and $G\bar{G}$, then we get

$$\eta_{1,k} = \frac{C_k (W - \frac{(J_1 + 2i\omega)J_2}{py_*})}{\int_0^{l\pi} \cos(kx) \cos(kx) dx \left[\frac{-(2i\omega + J_1)(l_1 + 2i\omega)}{py_*} - \frac{cz_* \alpha}{L^2} e^{-2i\omega\tau_c} - qz_* \right]},$$

$$\eta_{0,k} = \frac{C_k (S - \frac{J_1 l_2}{py_*})}{\int_0^{l\pi} \cos(kx) \cos(kx) dx \left[\frac{-J_1 l_1}{py_*} - \frac{cz_* \alpha}{L^2} - qz_* \right]}, \quad (3.18)$$

$$\zeta_{1,k} = \frac{C_k}{\int_0^{l\pi} \cos(kx) \cos(kx) dx} \cdot \frac{J_2}{py_*} - \frac{l_1 + 2i\omega}{py_*} \cdot \eta_{1,k},$$

$$\zeta_{0,k} = \frac{C_k}{\int_0^{l\pi} \cos(kx) \cos(kx) dx} \cdot \frac{l_2}{py_*} - \frac{l_1}{py_*} \cdot \eta_{0,k},$$

where

$$\begin{aligned}
 W &= \frac{-c\eta z_* \alpha}{L^3} e^{-2i\omega\tau_c} h_{11}^2 + \frac{c(2\eta y_* z_* s + \eta y_* + \alpha)}{L^3} e^{i\omega\tau_c} - \frac{cy_* s \beta}{L^3} h_{12}^2 - q h_{11} h_{12}, \\
 S &= \frac{-c\eta z_* \alpha}{L^3} 2h_{11} \bar{h}_{11} + \frac{c(2\eta y_* z_* s + \eta y_* + \alpha)}{L^3} (e^{-i\omega\tau_c} h_{11} \bar{h}_{12} + e^{i\omega\tau_c} \bar{h}_{11} h_{12}) - \frac{cy_* s \beta}{L^3} 2h_{12} \bar{h}_{12} - q(h_{11} \bar{h}_{12} + h_{12} \bar{h}_{11}), \\
 J_1 &= d_2 k^2 - \frac{cy_* \beta}{L^2} + b + q y_*, \quad J_2 = -\frac{r}{K} h_{11}^2 - p h_{11} h_{12}, \\
 l_1 &= a - r + \frac{2ry_*}{K} + pz_* + d_1 k^2, \quad l_2 = -\frac{r}{K} 2h_{11} \bar{h}_{11} - p(h_{11} \bar{h}_{12} + h_{12} \bar{h}_{11}), \\
 L &= 1 + \eta y_* + sz_*, \quad \alpha = 1 + sz_*, \quad \beta = 1 + \eta y_*.
 \end{aligned}$$

Specifically, if $n = 0$, the condition for $C_k \neq 0$ is $k = 0$. Thus we consider $n = k = 0$, then we have $C_k = l\pi$, $\int_0^{l\pi} \cos(nx) \cos(kx) dx = l\pi$. Thus we can simply get the value of $\eta_{1,0}$, $\eta_{0,0}$, $\zeta_{1,0}$, $\zeta_{0,0}$. For the ε^3 -order terms, we get

$$\left\{ \begin{aligned}
 &D_0 y_3 + \tau_c \left(a - r + \frac{2ry_*}{K} + pz_* \right) y_3 - d_1 \tau_c \Delta y_3 + \tau_c p y_* z_3 \\
 &= \mu d_1 \Delta y_2 - \mu \left(a - r + \frac{2ry_*}{K} + pz_* \right) y_2 - D_2 y_1 - D_1 y_2 \\
 &\quad - \mu p y_1 z_1 - \mu p y_* z_2 - \frac{\mu r y_1^2}{K} - \frac{2\tau_c r y_2 y_1}{K} - \tau_c p y_1 z_2 - \tau_c p y_2 z_1, \\
 &D_0 z_3 - \tau_c d_2 \Delta z_3 - \frac{\tau_c c z_* \alpha}{L^2} y_{31} - \left(\tau_c \frac{cy_* \beta}{L^2} - b - q y_* \right) z_3 \\
 &= -D_2 z_1 - D_1 z_2 + \tau_c \left[\frac{-c z_* \alpha D_1 y_{21} - c z_* \alpha D_2 y_{11}}{L^2} \right. \\
 &\quad \left. - \frac{-2c\eta z_* \alpha D_1 y_{11}^2 + 2c\eta z_* \alpha y_{11} y_{21}}{L^3} + \frac{c(2\eta y_* z_* s + \eta y_* + \alpha) y_{11} z_2}{L^3} \right. \\
 &\quad \left. + \frac{c(2\eta y_* z_* s + \eta y_* + \alpha)(-D_1 y_{11} z_1 + y_{21} z_1)}{L^3} - \frac{2cy_* s \beta z_1 z_2}{L^3} \right. \\
 &\quad \left. + \frac{c(-1 + z_*(-2\eta y_* - 1)s) s y_{11} z_1^2}{L^4} + \frac{cy_* s^2 \beta z_1^3}{L^4} + \frac{c z_* \eta^2 \alpha y_{11}^3}{L^4} \right. \\
 &\quad \left. + c\eta \left[\frac{3sz_* \alpha}{L^4} - \frac{2sz_* + 1}{L^3} \right] y_{11}^2 z_1 - q y_1 z_2 - q y_2 z_1 \right] \\
 &+ \mu \left[d_2 \Delta z_2 + \frac{-c z_* \alpha D_1 y_{11} + c z_* \alpha y_{21}}{L^2} + \left(\frac{cy_* \beta}{L^2} - b - q y_* \right) z_2 \right. \\
 &\quad \left. - \frac{c\eta z_* \alpha y_{11}^2}{L^3} + \frac{c(2\eta y_* z_* s + \eta y_* + \alpha) y_{11} z_1}{L^3} - \frac{cy_* \beta s z_1^2}{L^3} - q y_1 z_1 - q y_2 z_* \right],
 \end{aligned} \right. \quad (3.19)$$

where L, α, β are given by Eq (3.2). We substitute solution Eqs (3.13) and (3.17) into Eq (3.19), then denote the coefficient vector of $e^{i\omega\tau_c T_0}$ as m_2 , which satisfies the solvability condition

$$\langle h^*, (m_2, \cos(nx)) \rangle = 0.$$

Since μ is the disturbance parameter and μ^2 has very little influence on the result, the items containing $\mu^2 G$ can be ignored. Then we obtain

$$\frac{\partial G}{\partial T_2} = \chi G^2 \bar{G},$$

where

$$\chi = \frac{RC_k + Q}{V}, \quad (3.20)$$

with

$$\begin{aligned} R = & \bar{h}_{21} \left[-\frac{2\tau_c r}{K} (h_{11} \sum_{k=0}^{+\infty} \eta_{0,k} + \bar{h}_{11} \sum_{k=0}^{+\infty} \eta_{1,k}) - \tau_c p (h_{11} \sum_{k=0}^{+\infty} \zeta_{0,k} + \bar{h}_{11} \sum_{k=0}^{+\infty} \zeta_{1,k} + h_{12} \sum_{k=0}^{+\infty} \eta_{0,k} + \bar{h}_{12} \sum_{k=0}^{+\infty} \eta_{1,k}) \right] \\ & + \bar{h}_{22} \tau_c \left[-\frac{2c\eta z_* \alpha}{L^3} (e^{-i\omega\tau_c} h_{11} \sum_{k=0}^{+\infty} \eta_{0,k} + e^{-i\omega\tau_c} \bar{h}_{11} \sum_{k=0}^{+\infty} \eta_{1,k}) + \frac{c(2\eta y_* z_* s + \eta y_* + \alpha)}{L^3} (e^{-i\omega\tau_c} h_{11} \sum_{k=0}^{+\infty} \zeta_{0,k} \right. \\ & \left. + e^{i\omega\tau_c} \bar{h}_{11} \sum_{k=0}^{+\infty} \zeta_{1,k} + h_{12} \sum_{k=0}^{+\infty} \eta_{0,k} + \bar{h}_{12} \sum_{k=0}^{+\infty} \eta_{1,k}) - \frac{2cy_* s \beta}{L^3} (h_{12} \sum_{k=0}^{+\infty} \zeta_{0,k} + \bar{h}_{12} \sum_{k=0}^{+\infty} \zeta_{1,k}) \right], \end{aligned}$$

$$\begin{aligned} Q = & \bar{h}_{22} \tau_c \left[\frac{c(-1 + z_* (-2\eta y_* - 1)s)s}{L^4} (2e^{-i\omega\tau_c} h_{11} h_{12} \bar{h}_{12} + e^{i\omega\tau_c} \bar{h}_{11} h_{12}^2) + \frac{cy_* \beta s^2}{L^4} (2h_{12}^2 \bar{h}_{12}) \right. \\ & \left. + \frac{cz_* \eta^2 \alpha}{L^4} (2e^{-i\omega\tau_c} h_{11}^2 \bar{h}_{11}) + c\eta \left[\frac{3sz_* \alpha}{L^4} - \frac{2sz_* + 1}{L^3} \right] (e^{-2i\omega\tau_c} h_{11}^2 \bar{h}_{12} + 2h_{11} \bar{h}_{11} h_{12}) \right. \\ & \left. - q (h_{11} \sum_{k=0}^{+\infty} \zeta_{0,k} + \bar{h}_{11} \sum_{k=0}^{+\infty} \zeta_{1,k} + h_{12} \sum_{k=0}^{+\infty} \eta_{0,k} + \bar{h}_{12} \sum_{k=0}^{+\infty} \eta_{1,k}) \right] \int_0^{l\pi} \cos^4(nx) dx, \end{aligned}$$

$$V = \left[h_{11} \bar{h}_{21} + h_{12} \bar{h}_{22} + \frac{\tau_c cz_* \alpha}{L^2} e^{-i\omega\tau_c} h_{11} \bar{h}_{22} \right] \int_0^{l\pi} \cos(nx) \cos(nx) dx,$$

$$L = 1 + \eta y_* + sz_*,$$

$$\alpha = 1 + sz_*,$$

$$\beta = 1 + \eta y_*.$$

Therefore, the normal form of the Hopf bifurcation for system Eq (1.3) reduced on the center manifold is

$$\dot{G} = M\mu G + \chi G^2 \bar{G}, \quad (3.21)$$

where M and χ are given by Eqs (3.16) and (3.20), respectively. Now introduce $G = re^{i\theta}$ and put it into the normal form Eq (3.21), then one has

$$\begin{cases} \dot{r} = \operatorname{Re}(M)\mu r + \operatorname{Re}(\chi)r^3, \\ \dot{\theta} = \operatorname{Im}(M)\mu + \operatorname{Im}(\chi)r^2. \end{cases} \quad (3.22)$$

For the stability of the periodic solutions of system (1.3), we have the following result.

Theorem 2. When $\frac{\operatorname{Re}(M)\mu}{\operatorname{Re}(\chi)} < 0$, system Eq (1.3) exists as periodic solutions near the positive constant steady state solution E_* . Moreover,

- (i) If $\operatorname{Re}(M)\mu < 0$, the bifurcating periodic solutions reduced on the center manifold are unstable, and when $\mu > 0$ ($\mu < 0$), the direction of bifurcation is forward (backward);
- (ii) If $\operatorname{Re}(M)\mu > 0$, the bifurcating periodic solutions reduced on the center manifold are stable, and when $\mu > 0$ ($\mu < 0$), the direction of bifurcation is forward (backward).

4. Numerical simulations

In this section, we will perform numerical simulations for different values of τ . Based on the work of Komarova et al. [1], we fix

$$\begin{aligned} a &= 3.0 \text{ day}^{-1}, & p &= 1.0 \text{ mm}^3 \text{ cells}^{-1} \text{ day}^{-1}, \\ q &= 1.0 \text{ mm}^3 \text{ virus}^{-1} \text{ day}^{-1}, & r &= 6.0 \text{ day}^{-1}. \end{aligned}$$

For the remaining parameters, we consider the actual meaning of the parameters and choose

$$\begin{aligned} d_1 &= 0.4 \text{ mm}^{-3} \text{ day}^{-1}, & K &= 10 \text{ virus mm}^{-3}, & b &= 2 \text{ day}^{-1}, \\ d_2 &= 0.1 \text{ mm}^{-3} \text{ day}^{-1}, & c &= 6.5 \text{ mm}^3 \text{ virus}^{-1} \text{ day}^{-1}, \\ \eta &= 0.35 \text{ mm}^{-1} \text{ virus}, & s &= 0.02 \text{ mm}^3 \text{ immune cells}^{-1}, & l &= 2. \end{aligned}$$

It is easy to check that the condition (ii) of Lemma 1 is satisfied, which implies that the system (1.3) has only one positive constant steady state solution,

$$E_* = (y_*, z_*) = (0.4600, 2.7239).$$

In addition, we can also find that this set of parameters satisfies the condition (H2) of Lemma 3. Furthermore, by Eqs (2.10), (2.12) and (2.14), we obtain

$$\omega_0^+ = 2.1289, \quad I_1 = \{n = 0, 1, 2, 3\}, \quad \tau_c = \tau_{0,0}^+ = 0.0667.$$

Therefore, by Theorem 2.1, E_* is locally asymptotically stable when $\tau \in [0, \tau_c) = [0, 0.0667)$, and unstable when $\tau \in (0.0667, +\infty)$. Take $\tau = 0.055 \in [0, 0.0667)$ as an example, then E_* is locally asymptotically stable as is illustrated by the computer simulations (see Figure 1).

Biologically, when the virus stimulation delay does not exceed the threshold, immune cells can control the virus in the long-term at low levels. Although the virus is not completely eliminated, it does not cause serious disease deterioration, this is the ideal scenario that we hope for.

According to Eqs (3.16) and (3.20), we can get

$$M = 0.3874 - 10.6020i, \quad \chi = -0.4221 - 0.2652i,$$

which implies that $\operatorname{Re}(M) > 0$, and $\operatorname{Re}(\chi) < 0$. From Theorem 2, when $\mu > 0$, system (1.3) has stable bifurcating periodic solutions. In addition, the direction of the Hopf bifurcation is forward. Take $\tau = 0.067 \in (0.0667, +\infty)$ as an example, then system (1.3) generates a spatially homogeneous stable periodic solution (see Figure 2, where Figure 2(a), (c) depict simulations of the virus and immune cell dynamics, respectively, while Figure 2(b), (d) represent their respective local zoom-in plots).




Figure 1. Choose the initial function as $(0.4600 + 0.0001 \cos x, 2.7239 + 0.002 \cos x)$, then the constant steady state solution $E_* = (0.4600, 2.7239)$ of system (1.3) is locally asymptotically stable when $\tau = 0.055 < \tau_c$.




Figure 2. Choose the initial function as $(0.4600 + 0.0001 \cos x, 2.7239 + 0.002 \cos x)$, then system (1.3) has a spatially homogeneous stable periodic solution when $\tau = 0.067 > \tau_c$.

Biologically, when the virus stimulation delay slightly exceeds the threshold τ_c , the densities of immune cells and virus exhibits periodic oscillations. As the number of immune cells increases, they effectively control the virus and reduce the viral load. After a while, an immunoevasion mechanism for the virus may emerge and cause the number of immune cells to drop, allowing the virus to remultiply. This scenario is not ideal, but it is still manageable.

Once τ significantly exceeds the threshold, take $\tau = 0.076 \in (0.0667, +\infty)$ as an example, the virus proliferates rapidly (see Figure 3). This is the worst-case scenario, as the virus could spread rapidly and pose significant risks to the host.




Figure 3. Choose the initial function as $(0.4600 + 0.0001 \cos x, 2.7239 + 0.002 \cos x)$, then the constant steady state solution E_* of system (1.3) is unstable when $\tau = 0.076 > \tau_c$.

5. Conclusions

In this paper, we incorporated diffusion into an immunosuppressive infection model with virus stimulation delay and Beddington-DeAngelis functional response. We studied the stability of the constant steady state solution of the model and provided conditions for the occurrence of Hopf bifurcation. Moreover, we analyzed the stability and direction of the Hopf bifurcation, and further derived the normal form. By analyzing the model, we obtained a threshold τ_c for the virus stimulation delay τ and discovered that when τ was less than this threshold, the constant steady state solution was locally asymptotically stable. However, once τ exceeded the threshold, the constant steady state solution lost stability, and the model exhibited stable periodic solutions. This implied that when the virus could quickly stimulate immune cells, the host possessed strong immunity, which could inhibit virus growth and spread. Conversely, rapid virus proliferation posed significant risks to the host. The discovery of the threshold could help biologists predict, judge, and control the growth of virus cells and select effective treatment strategies.

Use of AI tools declaration

The authors declare they have not used Artificial Intelligence (AI) tools in the creation of this article.

Acknowledgments

This study was funded by Fundamental Research Funds for the Central Universities of China (Grant No.2572022DJ07).

Conflict of interest

The authors declare there is no conflicts of interest.

References

1. N. L. Komarova, E. Barnes, P. Klenerman, D. Wodarz, Boosting immunity by antiviral drug therapy: a simple relationship among timing, efficacy, and success, *Proc. Natl. Acad. Sci.*, **100** (2003), 1855–1860. <https://doi.org/10.1073/pnas.0337483100>
2. H. Dahari, A. Lo, R. M. Ribeiro, A. S. Perelson, Modeling hepatitis C virus dynamics: Liver regeneration and critical drug efficacy, *J. Theor. Biol.*, **247** (2007), 371–381. <https://doi.org/10.1016/j.jtbi.2007.03.006>
3. R. M. Anderson, G. F. Medley, R. M. May, A. M. Johnson, A preliminary study of the transmission dynamics of the human immunodeficiency virus (HIV), the causative agent of AIDS, *Math. Med. Biol.*, **3** (1986), 229–263. <https://doi.org/10.1093/imammb/3.4.229>
4. L. Zou, S. Ruan, W. Zhang, An age-structured model for the transmission dynamics of hepatitis B, *SIAM J. Appl. Math.*, **70** (2010), 3121–3139. <https://doi.org/10.1137/090777645>
5. R. S. Wijaya, S. A. Read, S. P. Selvamani, S. Schibeci, M. K. Azardaryany, A. Ong, et al., Hepatitis C virus (HCV) eradication with interferon-free direct-acting antiviral-based therapy results in KLRG1+ HCV-specific memory natural killer cells, *J. Infect. Dis.*, **223** (2021), 1183–1195. <https://doi.org/10.1093/infdis/jiaa492>
6. R. Wagner, J. T. Randolph, S. V. Patel, L. Nelson, M. A. Matulenko, R. Keddy, et al., Highlights of the structure-activity relationships of benzimidazole linked pyrrolidines leading to the discovery of the hepatitis C virus NS5A inhibitor pibrentasvir (ABT-530), *J. Med. Chem.*, **61** (2018), 4052–4066. <https://doi.org/10.1021/acs.jmedchem.8b00082>
7. A. Suk-Fong Lok, Hepatitis B treatment: what we know now and what remains to be researched, *Hepatol. Commun.*, **3** (2019), 8–19. <https://doi.org/10.1002/hep4.1281>
8. Z. Meng, Y. Chen, M. Lu, Advances in targeting the innate and adaptive immune systems to cure chronic hepatitis B virus infection, *Front. Immunol.*, **10** (2020), 3127. <https://doi.org/10.3389/fimmu.2019.03127>
9. M. P. Davenport, D. S. Khoury, D. Cromer, S. R. Lewin, A. D. Kelleher, S. J. Kent, Functional cure of HIV: the scale of the challenge, *Nat. Rev. Immunol.*, **19** (2019), 45–54. <https://doi.org/10.1038/s41577-018-0085-4>
10. B. Autran, B. Descours, V. Avettand-Fenoel, C. Rouzioux, Elite controllers as a model of functional cure, *Curr. Opin. HIV AIDS*, **6** (2011), 181–187. <https://doi.org/10.1097/COH.0b013e328345a328>

11. S. Shi, J. Huang, Y. Kuang, S. Ruan, Stability and Hopf bifurcation of a tumor-immune system interaction model with an immune checkpoint inhibitor, *Commun. Nonlinear Sci. Numer. Simul.*, **118** (2023), 106996. <https://doi.org/10.1016/j.cnsns.2022.106996>
12. M. A. Benchaib, A. Bouchnita, V. Volpert, A. Makhoute, Mathematical modeling reveals that the administration of EGF can promote the elimination of lymph node metastases by PD-1/PD-L1 blockade, *Front. Bioeng. Biotechnol.*, **7** (2019), 104. <https://doi.org/10.3389/fbioe.2019.00104>
13. A. Friedman, X. Lai, Combination therapy for cancer with oncolytic virus and checkpoint inhibitor: A mathematical model, *PLoS One*, **13** (2018), e0192449. <https://doi.org/10.1371/journal.pone.0192449>
14. H. Shu, L. Wang, J. Watmough, Sustained and transient oscillations and chaos induced by delayed antiviral immune response in an immunosuppressive infection model, *J. Math. Biol.*, **68** (2014), 477–503. <https://doi.org/10.1007/s00285-012-0639-1>
15. C. Tian, W. Gan, P. Zhu, Stability analysis in a diffusional immunosuppressive infection model with delayed antiviral immune response, *Math. Methods Appl. Sci.*, **40** (2017), 4001–4013. <https://doi.org/10.1002/mma.4279>
16. J. Li, X. Ma, J. Li, D. Zhang, Dynamics of a chronic virus infection model with viral stimulation delay, *Appl. Math. Lett.*, **122** (2021), 107547. <https://doi.org/10.1016/j.aml.2021.107547>
17. D. Wodarz, *Killer Cell Dynamics: Mathematical and Computational Approaches to Immunology*, Springer, New York, 2007. <https://doi.org/10.1007/978-0-387-68733-9-1>
18. R. J. De Boer, A. S. Perelson, Towards a general function describing T cell proliferation, *J. Theor. Biol.*, **175** (1995), 567–576. <https://doi.org/10.1006/jtbi.1995.0165>
19. R. J. De Boer, A. S. Perelson, Target cell limited and immune control models of HIV infection: a comparison, *J. Theor. Biol.*, **190** (1998), 201–214. <https://doi.org/10.1006/jtbi.1997.0548>
20. J. R. Beddington, Mutual interference between parasites or predators and its effect on searching efficiency, *J. Anim. Ecol.*, **44** (1975), 331–340. <https://doi.org/10.2307/3866>
21. D. L. DeAngelis, R. A. Goldstein, R. V. O'Neill, A model for trophic interaction, *Ecology*, **56** (1975), 881–892. <https://doi.org/10.2307/1936298>
22. R. S. Cantrell, C. Cosner, On the dynamics of predator-prey models with the Beddington-DeAngelis functional response, *J. Math. Anal. Appl.*, **257** (2001), 206–222. <https://doi.org/10.1006/jmaa.2000.7343>
23. W. Chen, M. Wang, Qualitative analysis of predator-prey models with Beddington-DeAngelis functional response and diffusion, *Math. Comput. Model.*, **42** (2005), 31–44. <https://doi.org/10.1016/j.mcm.2005.05.013>
24. T. W. Hwang, Global analysis of the predator-prey system with Beddington-DeAngelis functional response, *J. Math. Anal. Appl.*, **281** (2003), 395–401. [https://doi.org/10.1016/S0022-247X\(02\)00395-5](https://doi.org/10.1016/S0022-247X(02)00395-5)
25. D. Wodarz, Ecological and evolutionary principles in immunology, *Ecol. Lett.*, **9** (2006), 694–705. <https://doi.org/10.1111/j.1461-0248.2006.00921.x>

26. A. M. Elaiw, S. A. Azoz, Global properties of a class of HIV infection models with Beddington-DeAngelis functional response, *Math. Methods Appl. Sci.*, **36** (2013), 383–394. <https://doi.org/10.1002/mma.2596>
27. G. Huang, W. Ma, Y. Takeuchi, Global analysis for delay virus dynamics model with Beddington-DeAngelis functional response, *Appl. Math. Lett.*, **24** (2011), 1199–1203. <https://doi.org/10.1016/j.aml.2011.02.007>
28. X. Wang, Y. Tao, X. Song, A delayed HIV-1 infection model with Beddington-DeAngelis functional response, *Nonlinear Dyn.*, **62** (2010), 67–72. <https://doi.org/10.1007/s11071-010-9699-1>
29. Y. Chen, L. Wang, Z. Liu, Y. Wang, Complex dynamics for an immunosuppressive infection model with virus stimulation delay and nonlinear immune expansion, *Qual. Theory Dyn. Syst.*, **22** (2023), 118. <https://doi.org/10.1007/s12346-023-00814-y>



AIMS Press

©2023 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>)